152 related articles for article (PubMed ID: 10100556)
21. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation.
Schetelig J; Fetscher S; Reichle A; Berdel WE; Beguin Y; Brunet S; Caballero D; Majolino I; Hagberg H; Johnsen HE; Kimby E; Montserrat E; Stewart D; Copplestone A; Rösler W; Pavel J; Kingreen D; Siegert W
Haematologica; 2003 Nov; 88(11):1272-8. PubMed ID: 14607756
[TBL] [Abstract][Full Text] [Related]
22. Recurrence with histological transformation 40 days after autologous peripheral blood stem cell transplantation (APBSCT) for cutaneous CD30-negative large T cell lymphoma.
Nishio M; Sawada K; Koizumi K; Tarumi T; Takano H; Endo T; Takashima H; Hashimoto H; Haseyama Y; Kobayashi H; Koike T
Bone Marrow Transplant; 1998 Dec; 22(12):1211-4. PubMed ID: 9894726
[TBL] [Abstract][Full Text] [Related]
23. Autologous stem cell transplantation in advanced follicular lymphoma. A single center experience.
López R; Martino R; Sureda A; Nomdedéu J; Briones J; Martin-Henao G; García J; Brunet S; Sierra J
Haematologica; 1999 Apr; 84(4):350-5. PubMed ID: 10190950
[TBL] [Abstract][Full Text] [Related]
24. Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry.
Jantunen E; Canals C; Rambaldi A; Ossenkoppele G; Allione B; Blaise D; Conde E; Tilly H; Cook G; Clark F; Gallamini A; Haynes A; Mounier N; Dreger P; Pfreundschuh M; Sureda A;
Haematologica; 2008 Dec; 93(12):1837-42. PubMed ID: 18838474
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
26. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas.
Blystad AK; Enblad G; Kvaløy S; Berglund A; Delabie J; Holte H; Carlson K; Kvalheim G; Bengtsson M; Hagberg H
Bone Marrow Transplant; 2001 Apr; 27(7):711-6. PubMed ID: 11360110
[TBL] [Abstract][Full Text] [Related]
27. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group.
Rodríguez J; Conde E; Gutiérrez A; Arranz R; León A; Marín J; Bendandi M; Albo C; Caballero MD;
Eur J Haematol; 2007 Jul; 79(1):32-8. PubMed ID: 17598836
[TBL] [Abstract][Full Text] [Related]
28. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
[TBL] [Abstract][Full Text] [Related]
29. High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT).
Bengala C; Guarneri V; Ledermann J; Rosti G; Wandt H; Lotz JP; Cure JH; Orlandini C; Ferrante P; Conte PF; Demirer T;
Bone Marrow Transplant; 2005 Jul; 36(1):25-31. PubMed ID: 15908977
[TBL] [Abstract][Full Text] [Related]
30. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
[TBL] [Abstract][Full Text] [Related]
31. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
Rodríguez J; Conde E; Gutiérrez A; Arranz R; Gandarillas M; Leon A; Ojanguren J; Sureda A; Carrera D; Bendandi M; Moraleda J; Ribera JM; Albo C; Morales A; García JC; Fernández P; Cañigral G; Bergua J; Caballero MD;
Eur J Haematol; 2007 Apr; 78(4):290-6. PubMed ID: 17378891
[TBL] [Abstract][Full Text] [Related]
32. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
Ganguly S; Divine CL; Deauna-Limayo D; Bodensteiner DC; Cook JD; Lewis JN; Skikne BS
Ann Hematol; 2005 Aug; 84(8):526-31. PubMed ID: 15915350
[TBL] [Abstract][Full Text] [Related]
33. [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients].
Jin FY; Zou DH; Wang GR; Xu Y; Feng SZ; Zhao YZ; Han MZ; Yan WW; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):645-8. PubMed ID: 16620547
[TBL] [Abstract][Full Text] [Related]
34. Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French registry.
Moreau P; Fleury J; Brice P; Colombat P; Bouabdallah R; Lioure B; Voillat L; Casasnovas O; François S; Sadoun A; Lamy T; Lotz JP; Munck JN; Divine M; Fermé C; Pény AM; Fruchart C; Oriol P; Ojeda M; Reman O; Milpied N; Gisselbrecht C; Legros M; Harousseau JL
Bone Marrow Transplant; 1998 Apr; 21(8):787-93. PubMed ID: 9603402
[TBL] [Abstract][Full Text] [Related]
35. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit.
Kurian S; Qazilbash M; Fay J; Wolff S; Herzig R; Hobbs G; Bunner P; Weisenborn R; Aya-Ay M; Lynch J; Ericson S
Breast J; 2006; 12(6):531-5. PubMed ID: 17238982
[TBL] [Abstract][Full Text] [Related]
36. Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience.
Ballova V; Ladicka M; Vranovsky A; Lakota J
Neoplasma; 2008; 55(5):428-36. PubMed ID: 18665754
[TBL] [Abstract][Full Text] [Related]
37. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens.
Salar A; Sierra J; Gandarillas M; Caballero MD; Marín J; Lahuerta JJ; García-Conde J; Arranz R; León A; Zuazu J; García-Laraña J; López-Guillermo A; Sanz MA; Grañena A; García JC; Conde E;
Bone Marrow Transplant; 2001 Feb; 27(4):405-12. PubMed ID: 11313670
[TBL] [Abstract][Full Text] [Related]
38. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.
Federico M; Bellei M; Brice P; Brugiatelli M; Nagler A; Gisselbrecht C; Moretti L; Colombat P; Luminari S; Fabbiano F; Di Renzo N; Goldstone A; Carella AM;
J Clin Oncol; 2003 Jun; 21(12):2320-5. PubMed ID: 12805333
[TBL] [Abstract][Full Text] [Related]
39. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of diffuse large B-cell lymphoma subgroups in patients undergoing autologous SCT.
Hallack Neto AE; Dulley FL; Coelho Siqueira SA; Pracchia LF; Belesso M; Saboya R; Sturaro D; Amigo-Filho JU; Mendrone Junior A; Chamone DA; Pereira J
Bone Marrow Transplant; 2009 Feb; 43(4):323-5. PubMed ID: 18850022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
